Giulia Valeria Bianchi

List of Publications by Year
in descending order

40 papers	5,969 citations	346980 22 h-index	371746 37 g-index
40 all docs	40 docs citations	40 times ranked	6482 citing authors

#	Article	IF	Citations
1	The TRAR gene classifier to predict response to neoadjuvant therapy in HER2â€positive and ERâ€positive breast cancer patients: an explorative analysis from the NeoSphere trial. Molecular Oncology, 2022, 16, 2355-2366.	2.1	3
2	Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9). Breast Cancer Research and Treatment, 2021, 190, 103-109.	1.1	3
3	Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Annals of Oncology, 2021, 32, 994-1004.	0.6	393
4	Is There Still a Role for Endocrine Therapy Alone in HR+/HER2â€“ Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. Breast Care, 2020, 15, 30-37.	0.8	0
5	Early Changes of the Standardized Uptake Values (SUVmax) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. Cancers, 2020, 12, 3314.	1.7	5
6	Oral Capecitabine-Vinorelbine Is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer. Cancers, 2020, 12, 617.	1.7	4
7	Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study. PLoS ONE, 2019, 14, e0220644.	1.1	6
8	Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives. Critical Reviews in Oncology/Hematology, 2019, 139, 53-66.	2.0	137
9	Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: The ASTER study. Breast Journal, 2019, 25, 237-242.	0.4	1
10	Targeted-Gene Sequencing to Catch Triple Negative Breast Cancer Heterogeneity before and after Neoadjuvant Chemotherapy. Cancers, 2019, 11, 1753.	1.7	16
11	Eribulin in â€œField Practiceâ€: More from the Italian Experience. Oncology, 2018, 94, 1-2.	0.9	4
12	Trastuzumab and Hypofractionated Whole Breast Radiotherapy: A Victorious Combination?. Clinical Breast Cancer, 2018, 18, e363-e371.	1.1	14
13	Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer. Breast Cancer Research, 2017, 19, 16.	2.2	83
14	Evaluation of Local Oncologic Safety in Nippleâ€“Areola Complex-sparing Mastectomy After Primary Chemotherapy: A Propensity Score-matched Study. Clinical Breast Cancer, 2017, 17, 219-231.	1.1	28
15	Pitfalls in oncology: a unique case of thoracic splenosis mimicking malignancy in a patient with resected breast cancer. Journal of Thoracic Disease, 2016, 8, E403-E407.	0.6	3
16	5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncology, The, 2016, 17, 791-800.	5.1	623
17	Factors influencing acute and late toxicity in the era of adjuvant hypofractionated breast radiotherapy. Breast, 2016, 29, 90-95.	0.9	31
18	Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge. Future Oncology, 2016, 12, 1413-1428.	1.1	24

#	Article	IF	Citations
19	Current challenges in HER2-positive breast cancer. Critical Reviews in Oncology/Hematology, 2016, 98, 211-221.	2.0	33
20	Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition. Oncotarget, 2016, 7, 255-265.	0.8	39
21	Did Circulating Tumor Cells Tell us all they Could? The Missed Circulating Tumor Cell Message in Breast Cancer. International Journal of Biological Markers, 2015, 30, 429-433.	0.7	26
22	18F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 818-830.	3.3	34
23	Prognosis of women with early breast cancer and PIK3CA mutations. Breast, 2015, 24, 283-284.	0.9	3
24	Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. Annals of Oncology, 2015, 26, 2429-2436.	0.6	106
25	Everolimus-based therapy in patients with hormone receptor-positive, HER2- advanced breast cancer: management considerations. Future Oncology, 2015, 11, 2251-2254.	1.1	1
26	Axillary lymph node dissection versus no dissection in patients with T1N0 breast cancer: A randomized clinical trial (INT09/98). Cancer, 2014, 120, 885-893.	2.0	68
27	Different biological and prognostic breast cancer populations identified by FDG-PET in sentinel node-positive patients: Results and clinical implications after eight-years follow-up. Breast, 2014, 23, 334-340.	0.9	1
28	Commentaries on Data Published by Riggio et al. and Discussion by Otterburn on Locoregional Risk Following Mastectomy After Lipofilling. Aesthetic Plastic Surgery, 2014, 38, 608-610.	0.5	1
29	Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer. Journal of Clinical Oncology, 2013, 31, 1157-1163.	0.8	342
30	Lapatinib and letrozole as first-line therapy for metastatic breast cancer: case report of bone metastasis 18 years later. Tumori, 2013, 99, 264e-8e.	0.6	0
31	Metastatic breast cancer treated with lapatinib with a prolonged benefit: a case report and a review of therapeutic options available. Tumori, 2013, 99, 269e-72e.	0.6	4
32	Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2012, 13, 25-32.	5.1	1,879
33	Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer. Journal of Clinical Oncology, 2012, 30, 1594-1600.	0.8	221
34	Pertuzumab â€“ a HER-2 Dimerisation Inhibitor â€“ for the Treatment of Breast and Other Cancers. , 2011, , 73-90.		0
35	Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer. Journal of Clinical Oncology, 2010, 28, 1131-1137.	0.8	214
36	Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy. Journal of Clinical Oncology, 2010, 28, 1138-1144.	0.8	593

#	Article	IF	Citations
37	Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptorâ€“Positive Breast Cancer. Journal of Clinical Oncology, 2009, 27, 2630-2637.	0.8	582
38	Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anti-Cancer Drugs, 2009, 20, 616-624.	0.7	102
39	The Total Neuropathy Score as an assessment tool for grading the course of chemotherapyâ€induced peripheral neurotoxicity: comparison with the National Cancer Instituteâ€Common Toxicity Scale. Journal of the Peripheral Nervous System, 2007, 12, 210-215.	1.4	204
40	Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-l-carnitine. European Journal of Cancer, 2005, 41, 1746-1750.	1.3	138